I am/have/had
I am looking for
Advanced Filters
Found 2 clinical trials
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
Part 2: Period A: Risankizumab or ustekinumab for 16 weeks. Period B: Risankizumab or no treatment for 36 weeks. Period C: Re-treatment with risankizumab for 16 weeks.
systemic therapy
ustekinumab
plaque psoriasis
risankizumab
inflammatory disease
- 0 views
- 19 Feb, 2024
A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease
The purpose of this study is to estimate and compare the incidence of overall malignancy, serious infection, and opportunistic infections between new users of ustekinumab and new users of other biologic therapies among adult participants with Crohn's disease (CD).
malignancy
crohn's disease
biologics
opportunistic infection
cancer
- 0 views
- 19 Feb, 2024